Colombia wants to produce Novartis's leukemia drug imatinib under a compulsory license, something it is allowed to do under its trade agreement with the USA, to bring the price down from $15,161/year (double the annual average income) to prices like those charged in India ($803/year). Read the rest
When Purdue Pharma's patent on the MS Contin was close to expiry, the Sackler family who owned the company spent millions trying to find a product that could replace the profits they'd lose from generic competition on MS Contin: the result was Oxycontin, a drug that went on to kill Americans at epidemic scale. Read the rest
Neven Mrgan takes a prescription drug called Cuprimine. Without it, he would slowly die from liver disease. Unfortunately, the price of Cuprimine has gone from $400-$1,700/month to $44,000/month. Curprimine is made by Valeant Pharmaceuticals, run by billionaire J. Michael Pearson. He's stepping down, not because he jacked up the price of Cuprimine and other medications, but because the company's misstated earnings hurt its stock value.
It's an open secret that the pharmaceutical industry spends billions marketing to doctors, deliberately misleading them about their products, raking in record profits that they shift into offshore tax-havens through legally questionable means, while lobbying for global treaties that benefit them at the expense of the sick. Read the rest
Jamie Love is one of the founders of Knowledge Ecology International (formerly the Consumer Project on Technology), a super-effective activist NGO that helped to establish low-cost, global access to HIV/AIDS drugs. Read the rest
Martin Shkreli, the notorious, most-hated-man-on-the-Internet pharma douchebro who was arrested last week for securities fraud, told the FBI that the only reason they bothered busting him for financial corruption is that he had made a spectacle out of himself with his pharma shenanigans. Read the rest
In 2014, US doctors wrote ~20,000 prescriptions for risperidone, quetiapine and other antipsychotics for children under the age of two; a cohort on whom these drugs have never been tested and for whom there is no on-label usage. Read the rest
Martin Shkreli, the hedge-fund douche-bro who hiked the price of an off-patent drug used by AIDS and cancer patients from $13.50 to $750, then promised to lower the prices after becoming the Most Hated Man on the Internet did no such thing, because he is a liar. Read the rest
Former hedge-fund manager Martin Shkreli became a poster child for greed and sleaze when he bought the only company that was tooled up to make an off-patent drug called Daraprim that people with HIV used to control parasitic toxoplasmosis infections and jacked the price from $13.50 per tablet to $750 per tablet. Read the rest
Peer review and replication are critical to the scientific method, but in medical trials, a combination of pharma company intransigence and scientists' fear of being pilloried for human error means that the raw data that we base life-or-death decisions upon is routinely withheld, meaning that the errors lurk undetected in the data for years -- and sometimes forever. Read the rest
Michael Geist writes, "Last year, the Canadian government trumpeted anti-counterfeiting legislation as a key priority. The bill raced through the legislative process in the winter and following some minor modifications after committee hearings, seemed set to pass through the House of Commons. Yet after committee approval, the bill suddenly stalled with little movement throughout the spring. Why did a legislative priority with all-party approval seemingly grind to a halt?" Read the rest
In America, more under-6 kids go to the emergency room from accidental overdose than from car-accidents -- they get hold of medicine and drink the whole bottle. Since 2007, epidemiologist Dr Daniel Budnitz has campaigned for the use of flow-restrictors in children's medicine bottles, which dramatically reduce the likelihood of an OD; manufacturers started adding restrictors to acetaminophen in 2011, but stopped there.
Flow restrictors have not been added to bottles of antihistamines, ibuprofen, and cough and cold preparations -- even where they contain the same concentration of acetaminophen as plain acetaminophen tinctures. These other medicines account for about half of all overdoses by small children.
In a long, investigative piece, Pro Publica and Consumer Reports exhaustively document the effectiveness of restrictors, the intransigence of bottom-line-focused pharmaceutical manufacturers, and the real risks of children's medicine overdoses.
An FDA mandate would solve the problem of liquid overdose at the stroke of a pen, but the FDA refuses, preferring a voluntary approach that is demonstrably not working -- and putting kids at risk. The incidence of overdose in small children is not only widespread -- it's rising. Flow-restrictors are cheap, effective low-hanging fruit. Restrictors were invented to improve dosing and reduce spills in adult medicine, and are thus of benefit to everyone, not just parents. Read the rest